Prelude Therapeutics (PRLD) Income from Continuing Operations (2019 - 2026)
Prelude Therapeutics (PRLD) reported Income from Continuing Operations of 34444000.0 for Q1 2026, up 40.15% on a YoY basis from 24576806.56 in Q1 2025, and down 90.49% sequentially from 18082000.0 in Q4 2025.
Prelude Therapeutics (PRLD) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Prelude Therapeutics (PRLD) has 8 years of Income from Continuing Operations data on file, last reported at 34444000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 40.15% year-over-year to 34444000.0; the trailing twelve-month figure through Mar 2026 stood at 149013000.0 (up 39.97% YoY), and the FY2025 full-year result was 316470000.0, up 1.83% from the prior year.
- Income from Continuing Operations retreated to 34444000.0 in Q1 2026, from 18082000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 18082000.0 in Q4 2025 to a low of 144438000.0 in Q4 2022.
- A 5-year average of 52379294.12 and a median of 41588000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations surged 83.64% in 2022 and slumped 112.54% in 2024, its largest moves.
- Tracing PRLD's Income from Continuing Operations over 5 years: stood at 144438000.0 in 2022, then jumped by 73.79% to 37861000.0 in 2023, then grew by 9.24% to 34363000.0 in 2024, then surged by 47.38% to 18082000.0 in 2025, then plunged by 90.49% to 34444000.0 in 2026.
- Business Quant data shows PRLD's Income from Continuing Operations at 34444000.0 in Q1 2026, 18082000.0 in Q4 2025, and 42020000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Prelude Therapeutics | 318.53 Mn | 173.93 Mn | - | -34.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34.44 Mn |
| Dec 31, 2025 | -18.08 Mn |
| Sep 30, 2025 | -42.02 Mn |
| Jun 30, 2025 | -54.47 Mn |
| Mar 31, 2025 | -57.55 Mn |
| Dec 31, 2024 | -34.36 Mn |
| Sep 30, 2024 | -76.48 Mn |
| Jun 30, 2024 | -79.85 Mn |
| Mar 31, 2024 | -77.64 Mn |
| Dec 31, 2023 | -37.86 Mn |
| Sep 30, 2023 | -35.99 Mn |
| Jun 30, 2023 | -37.80 Mn |
| Mar 31, 2023 | -38.22 Mn |
| Dec 31, 2022 | -144.44 Mn |
| Sep 30, 2022 | -42.51 Mn |
| Jun 30, 2022 | -37.16 Mn |
| Mar 31, 2022 | -41.59 Mn |
| Dec 31, 2021 | -108.38 Mn |
| Sep 30, 2021 | -170.14 Mn |
| Jun 30, 2021 | -159.02 Mn |